REGEN BIOPHARMA INC $0.7153
-
-
pipinghotlasagna 2 years ago bullish
RGBP filed an 8-K report with the SEC announcing that it’s subsidiary KCL shall be granted patent protection with regard to the NR2F6 cancer T-Cell activation patent. As well as this RGBP is working on getting a pink current status which could boost this stock further.
-
TrendyToros
Start your discussions now!
-